STOCK TITAN

[Form 4] Treace Medical Concepts, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Scot Michael Elder, Chief Legal & Compliance Officer and corporate secretary of Treace Medical Concepts (TMCI), reported a Form 4 disclosing an equity transaction dated 08/09/2025. The filing lists a transaction coded "F" involving 10,515 shares at a reported price of $0. After the reported transaction, Mr. Elder beneficially owns 566,149 shares, held directly.

The filing states the beneficial ownership total includes 480,103 restricted stock units and indicates no derivative securities were reported. This disclosure describes the insider's reported change in non-derivative equity holdings and the composition of the reported stake.

Scot Michael Elder, Chief Legal & Compliance Officer e segretario societario di Treace Medical Concepts (TMCI), ha presentato un Modulo 4 relativo a una transazione azionaria datata 08/09/2025. La dichiarazione riporta una operazione codificata "F" che riguarda 10,515 azioni a un prezzo indicato di $0. Dopo la transazione, il sig. Elder detiene beneficiariamente 566,149 azioni, in possesso diretto.

Il documento precisa che il totale della proprietà beneficiaria include 480,103 restricted stock units e indica che non sono stati segnalati strumenti derivati. Questa comunicazione descrive la variazione dichiarata delle partecipazioni non-derivate dell'insider e la composizione della posizione riportata.

Scot Michael Elder, Director Legal & de Cumplimiento y secretario corporativo de Treace Medical Concepts (TMCI), presentó un Formulario 4 que registra una transacción de acciones con fecha 08/09/2025. La presentación indica una operación codificada "F" por 10,515 acciones a un precio declarado de $0. Tras la operación, el Sr. Elder posee beneficiariamente 566,149 acciones, en tenencia directa.

El documento señala que la propiedad beneficiaria total incluye 480,103 unidades de acciones restringidas y aclara que no se reportaron valores derivados. Esta divulgación describe el cambio informado en las participaciones no derivadas del insider y la composición de su posición reportada.

Scot Michael Elder는 Treace Medical Concepts (TMCI)의 Chief Legal & Compliance Officer 겸 회사 비서로서 08/09/2025자 주식거래를 공시한 Form 4를 제출했습니다. 제출서에는 거래 코드가 "F"인 10,515주가 신고가 $0로 기재되어 있습니다. 해당 거래 이후 Elder 씨는 실질적으로 566,149주를 직접 보유하고 있습니다.

신고서에는 총 실질보유가 480,103개의 제한 주식 단위(RSUs)를 포함하며, 파생증권은 신고되지 않음으로 명시되어 있습니다. 이 공시는 내부자의 비파생 주식 보유 변화와 보고된 지분 구성 내용을 설명합니다.

Scot Michael Elder, Chief Legal & Compliance Officer et secrétaire de Treace Medical Concepts (TMCI), a déposé un Formulaire 4 révélant une opération sur titres en date du 08/09/2025. Le dossier mentionne une opération codée "F" portant sur 10,515 actions à un prix déclaré de $0. Après cette opération, M. Elder détient à titre bénéficiaire 566,149 actions, détenues directement.

Le document précise que la détention bénéficiaire totale comprend 480,103 unités d'actions restreintes et indique qu'aucun titre dérivé n'a été déclaré. Cette communication décrit la variation signalée des participations non dérivées de l'initié et la composition de la position déclarée.

Scot Michael Elder, Chief Legal & Compliance Officer und Unternehmenssekretär von Treace Medical Concepts (TMCI), reichte ein Formular 4 ein, das eine Aktien-Transaktion vom 08/09/2025 ausweist. Die Einreichung nennt eine mit "F" codierte Transaktion über 10,515 Aktien zu einem gemeldeten Preis von $0. Nach der angegebenen Transaktion besitzt Mr. Elder wirtschaftlich 566,149 Aktien, direkt gehalten.

Die Meldung stellt fest, dass das wirtschaftliche Eigentum insgesamt 480,103 Restricted Stock Units umfasst und weist aus, dass keine derivativen Wertpapiere gemeldet wurden. Diese Offenlegung beschreibt die gemeldete Änderung der nicht-derivativen Aktienbeteiligung des Insiders sowie die Zusammensetzung der angegebenen Position.

Positive
  • Clear disclosure of post-transaction beneficial ownership: 566,149 shares reported as directly held
  • Significant portion identified as restricted stock units: 480,103 RSUs explicitly included in the total
  • No derivative securities reported: Table II is empty, indicating only non-derivative activity
Negative
  • None.

Insights

TL;DR: Form 4 shows a coded "F" transaction of 10,515 shares, leaving 566,149 shares beneficially owned (includes 480,103 RSUs).

The filing is limited to non-derivative activity: a transaction on 08/09/2025 recorded as code "F" for 10,515 shares at a reported price of $0. The post-transaction beneficial ownership is documented as 566,149 shares, with 480,103 restricted stock units included in that total. No options, warrants, or other derivatives are listed. From a reporting and disclosure perspective, this provides clear counts of direct holdings and restricted units.

TL;DR: Insider disclosure identifies direct beneficial ownership and restricted stock unit exposure, with a single non-derivative transaction coded "F".

The Form 4 identifies Scot Elder as the reporting officer and documents a non-derivative transaction on 08/09/2025. The record explicitly states 566,149 shares are beneficially owned directly, including 480,103 restricted stock units. The presence of an attorney-in-fact signature is indicated. The filing contains no derivative holdings and provides a straightforward update to the insider ownership record.

Scot Michael Elder, Chief Legal & Compliance Officer e segretario societario di Treace Medical Concepts (TMCI), ha presentato un Modulo 4 relativo a una transazione azionaria datata 08/09/2025. La dichiarazione riporta una operazione codificata "F" che riguarda 10,515 azioni a un prezzo indicato di $0. Dopo la transazione, il sig. Elder detiene beneficiariamente 566,149 azioni, in possesso diretto.

Il documento precisa che il totale della proprietà beneficiaria include 480,103 restricted stock units e indica che non sono stati segnalati strumenti derivati. Questa comunicazione descrive la variazione dichiarata delle partecipazioni non-derivate dell'insider e la composizione della posizione riportata.

Scot Michael Elder, Director Legal & de Cumplimiento y secretario corporativo de Treace Medical Concepts (TMCI), presentó un Formulario 4 que registra una transacción de acciones con fecha 08/09/2025. La presentación indica una operación codificada "F" por 10,515 acciones a un precio declarado de $0. Tras la operación, el Sr. Elder posee beneficiariamente 566,149 acciones, en tenencia directa.

El documento señala que la propiedad beneficiaria total incluye 480,103 unidades de acciones restringidas y aclara que no se reportaron valores derivados. Esta divulgación describe el cambio informado en las participaciones no derivadas del insider y la composición de su posición reportada.

Scot Michael Elder는 Treace Medical Concepts (TMCI)의 Chief Legal & Compliance Officer 겸 회사 비서로서 08/09/2025자 주식거래를 공시한 Form 4를 제출했습니다. 제출서에는 거래 코드가 "F"인 10,515주가 신고가 $0로 기재되어 있습니다. 해당 거래 이후 Elder 씨는 실질적으로 566,149주를 직접 보유하고 있습니다.

신고서에는 총 실질보유가 480,103개의 제한 주식 단위(RSUs)를 포함하며, 파생증권은 신고되지 않음으로 명시되어 있습니다. 이 공시는 내부자의 비파생 주식 보유 변화와 보고된 지분 구성 내용을 설명합니다.

Scot Michael Elder, Chief Legal & Compliance Officer et secrétaire de Treace Medical Concepts (TMCI), a déposé un Formulaire 4 révélant une opération sur titres en date du 08/09/2025. Le dossier mentionne une opération codée "F" portant sur 10,515 actions à un prix déclaré de $0. Après cette opération, M. Elder détient à titre bénéficiaire 566,149 actions, détenues directement.

Le document précise que la détention bénéficiaire totale comprend 480,103 unités d'actions restreintes et indique qu'aucun titre dérivé n'a été déclaré. Cette communication décrit la variation signalée des participations non dérivées de l'initié et la composition de la position déclarée.

Scot Michael Elder, Chief Legal & Compliance Officer und Unternehmenssekretär von Treace Medical Concepts (TMCI), reichte ein Formular 4 ein, das eine Aktien-Transaktion vom 08/09/2025 ausweist. Die Einreichung nennt eine mit "F" codierte Transaktion über 10,515 Aktien zu einem gemeldeten Preis von $0. Nach der angegebenen Transaktion besitzt Mr. Elder wirtschaftlich 566,149 Aktien, direkt gehalten.

Die Meldung stellt fest, dass das wirtschaftliche Eigentum insgesamt 480,103 Restricted Stock Units umfasst und weist aus, dass keine derivativen Wertpapiere gemeldet wurden. Diese Offenlegung beschreibt die gemeldete Änderung der nicht-derivativen Aktienbeteiligung des Insiders sowie die Zusammensetzung der angegebenen Position.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Elder Scot Michael

(Last) (First) (Middle)
C/O TREACE MEDICAL CONCEPTS, INC.
100 PALMETTO PARK PLACE

(Street)
PONTE VEDRA FL 32081

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
TREACE MEDICAL CONCEPTS, INC. [ TMCI ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legl & Comp Off, CorpSec
3. Date of Earliest Transaction (Month/Day/Year)
08/09/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 08/09/2025 F 10,515 D $0 566,149(1) D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Includes 480,103 restricted stock units.
/s/ Lisa Taylor as Attorney-in-fact for Scot Elder 08/12/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did the TMCI Form 4 report?

The Form 4 reports a transaction dated 08/09/2025 coded "F" involving 10,515 shares at a reported price of $0.

Who filed the Form 4 for TMCI and what is their role?

The reporting person is Scot Michael Elder, identified as Chief Legal & Compliance Officer and corporate secretary of Treace Medical Concepts.

How many TMCI shares does Scot Elder beneficially own after the reported transaction?

The filing shows 566,149 shares beneficially owned following the reported transaction, held directly.

Does the Form 4 disclose restricted stock units or derivatives for TMCI?

Yes. The filing states the beneficial ownership total includes 480,103 restricted stock units, and it discloses no derivative securities.

Who signed the Form 4 on behalf of Scot Elder?

The signature block shows the form was signed by Lisa Taylor as attorney-in-fact for Scot Elder.
Treace Medical Concepts, Inc.

NASDAQ:TMCI

TMCI Rankings

TMCI Latest News

TMCI Latest SEC Filings

TMCI Stock Data

435.89M
46.88M
25.81%
62.39%
4.36%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
PONTE VEDRA